Rheumaderm Current Issues in Rheumatology and Dermatology 1st Editon 2012 Softbound at Meripustak

Rheumaderm Current Issues in Rheumatology and Dermatology 1st Editon 2012 Softbound

Books from same Author: Carmel Mallia, Jouni Uitto

Books from same Publisher: Springer

Related Category: Author List / Publisher List


  • Retail Price: ₹ 7215/- [ 15.00% off ]

    Seller Price: ₹ 6133

Sold By: Book Upload      Click for Bulk Order

Offer 1: Get ₹ 111 extra discount on minimum ₹ 500 [Use Code: Bharat]

Offer 2: Get 15.00 % + Flat ₹ 100 discount on shopping of ₹ 1500 [Use Code: IND100]

Offer 3: Get 15.00 % + Flat ₹ 300 discount on shopping of ₹ 5000 [Use Code: MPSTK300]

Free Shipping (for orders above ₹ 499) *T&C apply.

In Stock

Free Shipping Available



Click for International Orders
  • Provide Fastest Delivery

  • 100% Original Guaranteed
  • General Information  
    Author(s)Carmel Mallia, Jouni Uitto
    PublisherSpringer
    Edition1st Edition
    ISBN9781461372035
    Pages562
    BindingSoftbound
    LanguageEnglish
    Publish YearOctober 2012

    Description

    Springer Rheumaderm Current Issues in Rheumatology and Dermatology 1st Editon 2012 Softbound by Carmel Mallia, Jouni Uitto

    1. The Interface between Rheumatology and Dermatology: Why Rheumaderm?.- 2. Nature and Nurture in Systemic Lupus Erythematosus.- 3. Heritable Connective Tissue Disorders.- 4. Neonatal Lupus Erythematosus.- 5. Prognosis in Juvenile Arthritis.- 6. Scleroderma in Children.- 7. Localized Morphea in Children.- 8. Autoimmune Thyroid Disorders in Juvenile Chronic Arthritis and Systemic Lupus Erythematosus.- 9. Prevalence of IgM-, IgA- and IgG-Rheumatoid Factors in Seronegative Polyarticular Disease Compared to Pauciarticular Disease in Juvenile Chronic Arthritis as Measured by ELISA.- 10. Incidence and Outcome of Kawasaki Disease in Malta.- 11. Systemic Sclerosis: AClinical Overview.- 12. Scleroderma Overlap Syndromes.- 13. Raynaud’s Phenomenon and Vascular Disease in Systemic Sclerosis.- 14. Linear Scleroderma en Coup de Sabre: Relationship with Progressive Facial Hemiatrophy (PFH).- 15. Scleroderma Profunda: Clinicopathological Studies.- 16. Early Diagnosis of Systemic Sclerosis.- 17. Cutaneous Necrotizing Vasculitis: Relation to Systemic Disease.- 18. Sjögren’s Syndrome: Autoimmune Epithelitis.- 19. Behçet’s Syndrome: The Cerrahpasa Experience H. Yazici and the Members of the Behçet’s Syndrome Research Centre.- 20. Autoantibodies in SLE: Disease Associations.- 21. Polymorphisms of the Xenobiotic-Metabolizing Enzymes CYP1A1 and NAT-2 in Systemic Sclerosis and Lupus Erythematosus.- 22. Elevated Soluble E-Selectin in Cutaneous Lupus Erythematosus.- 23. RNP Positivity in Maltese SLE Patients.- 24. Chilblain Lupus Erythematosus Is Associated with Antibodies to SSA/Ro.- 25. Male SLE Patients in Malta.- 26. Dermatomyositis: Diagnosis and Evaluation of Dermatomyositis, Polymyositis, Inclusion-Body Myositis.- 27. Dermatomyositis and Drugs.- 28. Dermatomyositis Associated with Malignancy: 12 Case Reports.- 29. Reactive Arthritis.- 30. Psoriatic Arthritis: Is Something Changing?.- 31. Incidence of Antiperinuclear Factor in Patients with Psoriatic Arthritis.- 32. Triggered Psoriasis.- 33. Pyridinium Crosslinks Excretion in Patients with Rheumatoid Arthritis: Correlation with Disease Activity and Glucocorticoid Treatment.- 34. Porphyria: From Sir Walter Raleigh to Molecular Biology.- 35. Photosensitivity and Joint Dysfunction.- 36. Role of Superantigens in Dermatology.- 37. Intravascular Lymphomatosis: A Report of Ten Patients with Central Nervous System Involvement and a Review of the Disease Process.- 38. Pemphigus and Diet: Have We Solved the Mystery of Fogo Selvagem?.- 39. The Treatment of Systemic Sclerosis.- 40. Enalapril (10 Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): Echocardiographic Substudy—Three Months Follow-Up..- 41. Enalapril (10 Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): ECG Exercise Testing—Three Months Follow-Up.- 42. Enalapril (10 Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): Pulmonary Substudy—Effects of Three Month Treatment.- 43. Enalapril (10Mg/Day) in Systemic Sclerosis: One Year, Double Blind, Randomised Study (ESS-1): Electrocardiographic Substudy—Three Months Follow-Up,.- 44. Treatment of Generalized Morphea with Oral 1.25- Dihydroxyvitamin D3.- 45. Vasospasmolytic Therapy in Patients with SSC.- 46. Biomechanical Stimulation Therapy: A Novel Physiotherapy Method for Systemic Sclerosis.- 47. Reduced Skin Stiffness by Grenz Ray Treatment in Generalized Morphea.- 48. NSAIDs/Corticosteroids—Primum Non Nocere.- 49. Management Issues in Vasculitis.- 50. Sulphasalazine: An Alternative Drug for Second-Line Treatment of Juvenile Chronic Arthritis.- 51. Cyclosporin A and Retinoids in Psoriasis.- 52. Methotrexate.- 53. Azathioprine in Dermatological Practice: An Overview with Special Emphasis on Its Use in Non-Bullous Inflammatory Dermatoses.- 54. The Effect of Methylprednisolone Pulse Therapy in Polymyositis/ Dermatomyos